Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

Clinician holding piggy bank | Image Credit: Dee Karen - stock.adobe.com
Oncology Biosimilars Offer Potential Relief From Financial Burden of Cancer Care

June 2nd 2025

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the 2025 American Society of Clinical Oncology Annual Meeting.

FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
FDA Approves Denosumab Biosimilars Stoboclo and Osenvelt

March 4th 2025

FDA Approved. | Image Credit: Nirusmee - stock.adobe.com
First Insulin Aspart Biosimilar Receives FDA Approval

February 20th 2025

Osteoporosis. | Image Credit: Nisit - stock.adobe.com
Denosumab Biosimilars Approved With Interchangeability to Address Osteoporosis, Fracture Risk

February 18th 2025

Insulin. | Image Credit: Sherry Young- stock.adobe.com
Biosimilar Insulin Linked to Lower Prices in Europe

February 12th 2025

Continuing Medical Education
View All
June 23rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
June 23rd 2025

New and Approved: FDA’s 2024 Drug Lineup

1.5 Credits / General Pharmacy
June 23rd 2025

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy
June 23rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Market share increase | Image Credit: Kiattisak - stock.adobe.com
October 15th 2024

Samsung Bioepis Reports 2024 Biosimilar Market Growth Trends

Cameron Santoro
Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.
FDA approve graphic on screen over a doctor | Image credit: wladimir1804 - stock.adobe.com
October 11th 2024

FDA Approves Imuldosa, a Fifth Biosimilar to Stelara

Skylar Jeremias
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
Cost reduction in health care. | Image Credit: wladimir1804 - stock.adobe.com
October 7th 2024

Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing

Cameron Santoro
Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira for the monthly dose.
Blue FDA approved stamp | Image credit: cartoon-stock - adobe.com
October 2nd 2024

Fourth Ustekinumab Biosimilar, Otulfi, Approved in US

Laura Joszt, MA
Otulfi from Formycon and Fresenius Kabi was approved simultaneously in the US and the European Union. In the US, it will launch in February 2025.
Follitropin alfa | Image Credit: cristianstorto - stock.adobe.com
September 30th 2024

Biosimilar Follitropin Alfa Offers Fertility Savings in France

Cameron Santoro
A French study found that follitropin alfa, a biosimilar fertility drug, is more cost-effective compared with its originator, leading to potential savings for both patients and the health care system.
Kirollos Hanna, PharmD
September 28th 2024

Role of the Pharmacist in the Care Team to Contain Costs in Oncology

Laura Joszt, MA
The pharmacist is a critical member of the care team to help manage patients on treatment and contain costs of cancer care, said Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy, Minnesota Oncology.
Cost savings | Image credit: joyfotoliakid - stock.adobe.com
September 27th 2024

Report Highlights Biosimilars Savings, but High Out-of-Pocket Costs for Patients

Julia Bonavitacola
Out-of-pocket costs for biosimilars and generics are still high for patients despite these drugs leading to estimated savings of $445 billion in 2023.
Rows of identical clear vials | Image credit: nordroden - stock.adobe.com
September 4th 2024

Drug Survival of Biosimilars, Originator TNF Inhibitors Similar

Laura Joszt, MA
The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry.
White piggy bank next to a stethoscope with health icons above it | Image credit: Kiattisak - stock.adobe.com
August 25th 2024

Biosimilar Updates: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results

Skylar Jeremias
Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.
Interest rates control inflation | Image Credit: Thongdee - stock.adobe.com
August 16th 2024

Biosimilar Uptake Lags in US Despite Potential Cost Savings

Cameron Santoro
Delayed biosimilar uptake in the US is driven by payer, provider, and patient barriers, but targeted interventions can help boost utilization and savings.
Kathy Oubre, MS | Image: LinkedIn
August 16th 2024

Biosimilars and Employers: Strategies for Success

Kathy Oubre, MS
This article first appeared on The Center for Biosimilars®.
eye and tech | Image credit: eevl - stock.adobe.com
August 13th 2024

FDA Approves Biosimilar Enzeevu for Eye Conditions

Skylar Jeremias
The FDA approved Sandoz’ Enzeevu, the fourth aflibercept biosimilar to be approved for Americans with age-related macular degeneration and other retinal eye diseases.
A panel of 4 experts on biosimilars
July 23rd 2024

Private Label Biosimilars

Sophia Humphreys, PharmD, MHA, BCBBS Chad Cannon, PharmD, BCCCP Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST Susan Peppers, RPh
The expert panel discusses the greater potential for private label biosimilars.
Close of up of an older woman's eye | Image credit: Syda Productions - stock.adobe.com
May 20th 2024

First Aflibercept Biosimilars Approved in US

Skylar Jeremias
The FDA approved the first 2 biosimilars referencing aflibercept (Eylea). However, patent litigation has left it unclear when the biosimilars will come to market.
AJMC
May 17th 2024

Budget Impact Analysis of Biosimilar Natalizumab in the US

Edward Li, PharmD, MPH Adrian Goh, MEc Soni Gupta, MEc Marion Schauf, Dipl-Kff Anna Chen, PharmD, MS Daniel M. Hartung, PharmD, MPH
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Woman sitting on bed with back pain illustrated by a highlighted spine | Image credit: WavebreakMediaMicro - stock.adobe.com
April 12th 2024

Radiographic Progression Low for High-Risk Patients With axSpA on Both Secukinumab and an Adalimumab Biosimilar

Kimberly Rath, PharmD
Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.
FDA approval stamp in red | Image credit: chrisdorney - stock.adobe.com
March 5th 2024

FDA Approves First 2 Denosumab Biosimilars

Laura Joszt, MA
Wyost and Jubbonti were approved as interchangeable biosimilars for Xgeva and Prolia; however, there is no launch date yet pending litigation with the maker of the reference products.
Doctor stacking wooden blocks with health care icons | image credit: REDPIXEL - stock.adobe.com
January 14th 2024

Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024

Jayne Hornung
Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.
stethoscope and gavel | Image credit: Andrey Popov - stock.adobe.com
January 1st 2024

CareFirst Files Lawsuit Against J&J Over Delay Tactics for Stelara Biosimilars

Laura Joszt, MA
While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.
Highlights from Asembia Speciality Pharmacy Summit 2023
December 31st 2023

Top 5 Content From Asembia 2023

The most popular content from our Asembia coverage largely covered biosimilars.
The Top 5 SAP Content of 2023
December 29th 2023

Top 5 Strategic Alliance Partnership Content of 2023

Laura Joszt, MA
Through interviews and contributed content, Strategic Alliance Partnerships provide insights into changes in health care delivery and medicine.
Blue FDA approved stamp on white background | Image credit: Olivier Le Moal - stock.adobe.com
December 19th 2023

FDA Approves Fifth Bevacizumab Biosimilar, Avzivi

Skylar Jeremias
Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) has become the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States.
Top 5 Biosimilar articles of 2023
December 18th 2023

Top 5 Most-Read Biosimilar Articles in 2023

Laura Joszt, MA
In 2023, adalimumab biosimilars took center stage in the biosimilar space due to 8 long-anticipated products finally launching.
Art of someone with giant scissors cutting a health care price tag | Image credit: retrostar - stock.adobe.com
December 16th 2023

Australian Government Pricing Policy Saved Over $6 Million After Etanercept Biosimilar Launched

Laura Joszt, MA
The government of Australia’s pricing policy links the price of new medications with similar safety and efficacy, resulting in significant savings over the first 3 years after the etanercept biosimilar Brenzys was introduced.
3D rendering of intestines | Image credit: sdecoret - stock.adobe.com
December 8th 2023

Safety, Efficacy of Adalimumab Biosimilar GP2017 Similar to Originator in IBD

Cameron Santoro
Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment.
Vial with eculizumab label with a needle | Image credit: luchschenF - stock.adobe.com
December 6th 2023

Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH

Laura Joszt, MA
ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Black patient speaking with doctor | Image credit: Dragana Gordic - stock.adobe.com
December 1st 2023

Patients With Rheumatic Diseases Report Low Satisfaction After Mandatory Biosimilar Switch

Laura Joszt, MA
A mandatory nationwide transition from reference adalimumab to a biosimilar was implemented in New Zealand.
Drug coverage represented by pills, health icons, and a stethoscope | Image credit: janews094 - stock.adobe.com
November 27th 2023

CVS Caremark Switches Up Biosimilar Coverage in 2024

Denise Myshko
As part of updates to its standard formulary, CVS Caremark has removed Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
Person filling out insurance paperwork | Image credit: sodawhiskey - stock.adobe.com
November 21st 2023

HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars

Lana Pine
Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Stethoscope with health icons next to a piggy bank | Image credit: Kiattisak - stock.adobe.com
November 20th 2023

Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models

Laura Joszt, MA
A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
<12345678
...
20>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo